Mesoblast Ltd Files 6-K with SEC

Ticker: MEOBF · Form: 6-K · Filed: Dec 12, 2025 · CIK: 1345099

Mesoblast LTD 6-K Filing Summary
FieldDetail
CompanyMesoblast LTD (MEOBF)
Form Type6-K
Filed DateDec 12, 2025
Risk Levellow
Pages1
Reading Time1 min
Sentimentneutral

Sentiment: neutral

Topics: sec-filing, 6-K, regulatory-update

Related Tickers: MESO

TL;DR

MESO files 6-K, attaching ASX announcement. Stay tuned for details.

AI Summary

On December 12, 2025, Mesoblast Limited filed a Form 6-K with the SEC, attaching a new release announcement made to the Australian Securities Exchange. The filing incorporates this announcement by reference, providing an update on the company's activities. Mesoblast Limited is incorporated in Australia and its principal executive offices are located in Melbourne.

Why It Matters

This filing indicates Mesoblast Limited is providing an update to the market and regulators, which could contain material information about its business operations or financial status.

Risk Assessment

Risk Level: low — This is a routine filing (6-K) that incorporates a press release, not indicating any immediate negative or positive event.

Key Numbers

Key Players & Entities

FAQ

What is the specific content of the new release announcement filed as Exhibit 99.1?

The provided text does not detail the content of the new release announcement, only that it was filed with the Australian Securities Exchange and is incorporated by reference into this 6-K filing.

When was the announcement incorporated by reference into the 6-K filing?

The announcement was incorporated by reference into the 6-K filing on December 12, 2025.

What is Mesoblast Limited's jurisdiction of incorporation?

Mesoblast Limited is incorporated in Australia.

Who is the Chief Executive Officer and Executive Director of Mesoblast Limited?

Silviu Itescu is the Chief Executive Officer and Executive Director of Mesoblast Limited.

What is the SIC code for Mesoblast Limited?

The Standard Industrial Classification (SIC) code for Mesoblast Limited is 2836, which corresponds to Biological Products (No Diagnostic Substances).

Filing Stats: 212 words · 1 min read · ~1 pages · Grade level 17.3 · Accepted 2025-12-11 20:09:01

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly organized. Mesoblast Limited s Paul Hughes Paul Hughes Company Secretary Dated December 12, 2025 INDEX TO EXHIBITS Item 99.1 Press release of Mesoblast Ltd, dated December 12, 2025.

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing